EP3666895A1 — Novel crispr enzymes and systems
Assigned to SHMAKOV, SERGEY · Expires 2020-06-17 · 6y expired
What this patent protects
The invention provides for methods for targeting nucleic acids. In particular, the invention provides a RNA-targeting system comprising a novel RNA-targeting CRISPR effector protein comprising HEPN domains and at least one targeting nucleic acid component like a guide RNA.
USPTO Abstract
The invention provides for methods for targeting nucleic acids. In particular, the invention provides a RNA-targeting system comprising a novel RNA-targeting CRISPR effector protein comprising HEPN domains and at least one targeting nucleic acid component like a guide RNA.
Drugs covered by this patent
- Onpattro (PATISIRAN SODIUM) · Alnylam Pharmaceuticals
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.